Oskar Hansson

List of Publications by Year
in descending order

514 papers	41,861 citations	1701 104 h-index
564 all docs	564 docs citations	564 times ranked

4012 176 g-index
29734 citing authors

#	Article	IF	Citations
1	Test–retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimer's and Dementia, 2023, 19, 797-806.	0.4	24
2	The <i>BIN1</i> rs744373 Alzheimer's disease risk SNP is associated with faster Aβ–associated tau accumulation and cognitive decline. Alzheimer's and Dementia, 2022, 18, 103-115.	0.4	24
3	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p–tau. Alzheimer's and Dementia, 2022, 18, 283-293.	0.4	72
4	Tau pathology mediates age effects on medial temporal lobe structure. Neurobiology of Aging, 2022, 109, 135-144.	1.5	8
5	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1295-1305.	1.3	10
6	Serum Neurofilament Light Chain as a Marker of Progression in Parkinson's Disease: Long-Term Observation and Implications of Clinical Subtypes. Journal of Parkinson's Disease, 2022, 12, 571-584.	1.5	13
7	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurology, The, 2022, 21, 66-77.	4.9	360
8	Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort. Journal of Parkinson's Disease, 2022, 12, 153-171.	1.5	5
9	Characterization of pre–analytical sample handling effects on a panel of Alzheimer's disease–related blood–based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. Alzheimer's and Dementia, 2022, 18, 1484-1497.	0.4	84
10	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization. Pain Reports, 2022, 7, e988.	1.4	8
11	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
12	Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology, 2022, 98, .	1.5	22
13	Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels. Acta Neuropathologica Communications, 2022, 10, 3.	2.4	36
14	Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer's Disease Pathology and Cognitive Decline. Biological Psychiatry, 2022, 92, 34-43.	0.7	21
15	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Alzheimer's and Dementia, 2022, 18, 2218-2233.	0.4	24
16	Components of gait in people with and without mild cognitive impairment. Gait and Posture, 2022, 93, 83-89.	0.6	7
17	Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention. Journal of Nuclear Medicine, 2022, 63, 981-985.	2.8	9
18	The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimer's Research and Therapy, 2022, 14, 26.	3.0	49

#	Article	IF	Citations
19	The Neuroinflammatory Acute Phase Response in Parkinsonian–Related Disorders. Movement Disorders, 2022, 37, 993-1003.	2.2	8
20	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. JAMA Neurology, 2022, 79, 149.	4.5	66
21	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. journal of prevention of Alzheimer's disease, The, 2022, 9, 197-210.	1.5	201
22	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology, 2022, 98, .	1.5	49
23	Subtypes of Alzheimer's disease: questions, controversy, and meaning. Trends in Neurosciences, 2022, 45, 342-345.	4.2	14
24	Midsagittal corpus callosal thickness and cognitive impairment in Parkinson's disease. European Journal of Neuroscience, 2022, 55, 1859-1872.	1.2	5
25	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients. Alzheimer's Research and Therapy, 2022, 14, 46.	3.0	17
26	The protective gene dose effect of the $APOE$ $\mu2$ allele on gray matter volume in cognitively unimpaired individuals. Alzheimer's and Dementia, 2022, 18, 1383-1395.	0.4	13
27	Association of CSF Aβ_{38} Levels With Risk of Alzheimer Disease–Related Decline. Neurology, 2022, 98, .	1.5	16
28	Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques. Neurology, 2022, 98, .	1.5	89
29	Blood–based biomarkers for Alzheimer's disease. EMBO Molecular Medicine, 2022, 14, e14408.	3.3	122
30	Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217. Alzheimer's Research and Therapy, 2022, 14, 67.	3.0	18
31	Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Lancet Neurology, The, 2022, 21, 726-734.	4.9	130
32	Astrocytic function is associated with both amyloid-β and tau pathology in non-demented $APOE$ $\mu4$ carriers. Brain Communications, 2022, 4, .	1.5	4
33	Tau PET Imaging in Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 20S-26S.	2.8	26
34	Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. Acta Neuropathologica Communications, 2022, 10, .	2.4	31
35	Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers. JAMA Neurology, 2022, 79, 797.	4.5	17
36	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. Neurology, 2021, 96, e193-e202.	1.5	54

#	Article	IF	Citations
37	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 683-691.	1.7	8
38	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age. Progress in Neurobiology, 2021, 198, 101904.	2.8	25
39	Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment. JAMA Neurology, 2021, 78, 229.	4.5	28
40	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging, 2021, 1, 114-123.	5.3	94
41	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2021, 8, 259-265.	1.7	25
42	Plasma Phospho‐Tau Identifies Alzheimer's Co‐Pathology in Patients with Lewy Body Disease. Movement Disorders, 2021, 36, 767-771.	2.2	34
43	Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease. Brain, 2021, 144, 310-324.	3.7	123
44	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurology, 2021, 78, 149.	4.5	176
45	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2245-2258.	3.3	27
46	SCRT1 is a novel beta cell transcription factor with insulin regulatory properties. Molecular and Cellular Endocrinology, 2021, 521, 111107.	1.6	4
47	Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment. European Radiology, 2021, 31, 666-673.	2.3	4
48	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. Current Opinion in Neurology, 2021, 34, 266-274.	1.8	54
49	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. Translational Psychiatry, 2021, 11, 76.	2.4	78
50	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. Scientific Reports, 2021, 11, 1965.	1.6	28
51	Biomarker testing in MCI patients—deciding who to test. Alzheimer's Research and Therapy, 2021, 13, 14.	3.0	6
52	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. Acta Neuropathologica Communications, 2021, 9, 19.	2.4	17
53	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. Alzheimer's Research and Therapy, 2021, 13, 38.	3.0	12
54	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2110-2120.	3.3	33

#	Article	IF	Citations
55	Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2097-2109.	3.3	34
56	Time between milestone events in the Alzheimer's disease amyloid cascade. NeuroImage, 2021, 227, 117676.	2.1	20
57	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2121-2139.	3.3	43
58	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. Alzheimer's and Dementia, 2021, 17, 1575-1582.	0.4	51
59	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. Alzheimer's Research and Therapy, 2021, 13, 68.	3.0	117
60	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2140-2156.	3.3	83
61	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain, 2021, 144, 2771-2783.	3.7	78
62	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2086-2096.	3.3	11
63	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2070-2085.	3.3	22
64	Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nature Medicine, 2021, 27, 871-881.	15.2	354
65	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2183-2199.	3.3	16
66	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 872-880.	0.9	17
67	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study. Alzheimer's and Dementia, 2021, 17, 1832-1842.	0.4	5
68	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1998-2008.	0.4	25
69	A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2295-2305.	3.3	41
70	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. Nature Medicine, 2021, 27, 1034-1042.	15.2	236
71	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Molecular Medicine, 2021, 13, e14022.	3.3	90
72	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain, 2021, 144, 2826-2836.	3.7	65

#	Article	IF	Citations
73	Biomarkers for neurodegenerative diseases. Nature Medicine, 2021, 27, 954-963.	15.2	399
74	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nature Communications, 2021, 12, 3555.	5.8	115
75	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	5.8	219
76	Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease. Psychiatry Research - Neuroimaging, 2021, 312, 111273.	0.9	11
77	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Molecular Medicine, 2021, 13, e14398.	3.3	58
78	Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. Brain, 2021, 144, 3505-3516.	3.7	198
79	Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis. Pain Practice, 2021, , .	0.9	5
80	Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience. European Radiology, 2021, , 1.	2.3	1
81	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. Alzheimer's Research and Therapy, 2021, 13, 138.	3.0	10
82	Management of Alzheimer's disease takes a leap forward. Lancet Neurology, The, 2021, 20, 586-587.	4.9	4
83	Cadmium and lead exposure and risk of dementia in a Swedish population-based cohort: The Malmö Diet and Cancer Study. ISEE Conference Abstracts, 2021, 2021, .	0.0	0
84	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. JAMA Neurology, 2021, 78, 961.	4.5	148
85	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. Neurology, 2021, 97, e1681-e1694.	1.5	60
86	Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease. JAMA Neurology, 2021, 78, 1375.	4.5	195
87	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurology, The, 2021, 20, 739-752.	4.9	220
88	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2259-2271.	3.3	10
89	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.4	174
90	Sex differences in off-target binding using tau positron emission tomography. NeuroImage: Clinical, 2021, 31, 102708.	1.4	21

#	Article	IF	Citations
91	The global Alzheimer's Association round robin study on plasma amyloid β methods. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12242.	1.2	17
92	Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease. Current Alzheimer Research, 2021, 18, 573-584.	0.7	3
93	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. Scientific Reports, 2021, 11, 19853.	1.6	6
94	Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A Report of an International Research Collaboration Network. Journal of Alzheimer's Disease, 2021, , 1-15.	1.2	1
95	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. Alzheimer's and Dementia, 2021, 17, .	0.4	6
96	Ability of tau‐PET, phospho‐tau217, NfL and cortical thickness to predict short‐term cognitive decline in early symptomatic Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
97	Unravelling drivers of age‐and beta‐amyloid‐related neurodegeneration in medial temporal lobe atrophy in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
98	Establishment of updated biomarker cut‐off values for the second‐generation Elecsys β‐amyloid(1–42), pTau and tTau CSF immunoassays. Alzheimer's and Dementia, 2021, 17, .	0.4	0
99	Soluble P‐tau217 reflects both amyloid and tau pathology in the human brain and mediates the association of amyloid with neocortical tau. Alzheimer's and Dementia, 2021, 17, .	0.4	0
100	Inflammatory, degeneration and neuritic growth biomarkers predict cognitive decline and dementia in Parkinson's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
101	Biomarker driven enrichment strategies for tau pathology in AD clinical trials. Alzheimer's and Dementia, 2021, 17, .	0.4	0
102	Impact of reduced injected dose on the quantification of [^{18} F]RO948 and [^{18} F]Flortaucipir PET for *in vivo* tau pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
103	Tau and synaptic biomarkers but not amyloid‐β are associated with cerebral perfusion in the Alzheimer's disease spectrum. Alzheimer's and Dementia, 2021, 17, .	0.4	0
104	Plasma glial fibrillary acidic protein is an early and specific marker of amyloid‐β pathology in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	1
105	Tau deposition is associated with grey matter network breakdown across different stages of the Alzheimer's disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	0
106	Plasma biomarkers predict longitudinal amyloid accumulation, tau burden, brain atrophy and cognitive decline in early Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
107	Lower cognitive resilience against brain atrophy in cognitively unimpaired elderly is partly explained by Alzheimer's disease pathology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
108	Towards a universal cortical tau sampling mask. Alzheimer's and Dementia, 2021, 17, .	0.4	3

#	Article	IF	Citations
109	Comparing the clinical utility and diagnostic performance of cerebrospinal fluid P–tau181, P–tau217 and P–tau231 assays. Alzheimer's and Dementia, 2021, 17, .	0.4	0
110	Amyloid–β accumulation is independently related to executive function in cognitively unimpaired adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
111	Associations between cerebrospinal fluid markers of neuroinflammation and longitudinal measurements of white matter lesions. Alzheimer's and Dementia, 2021, 17, .	0.4	0
112	Associations between longitudinal neuropsychiatric symptoms and biomarkers of beta–amyloid, tau, neurodegeneration, and cognitive decline. Alzheimer's and Dementia, 2021, 17, .	0.4	1
113	The association between diet in mid–life and dementia incidence over a 20–year period. Alzheimer's and Dementia, 2021, 17, .	0.4	0
114	Potential drivers of age– and beta–amyloid–related neurodegeneration in early and late Alzheimer's Disease regions in cognitively normal older adults. Alzheimer's and Dementia, 2021, 17, .	0.4	0
115	Prediction of future Alzheimer's disease dementia using plasma phospho–tau combined with other accessible measures. Alzheimer's and Dementia, 2021, 17, .	0.4	2
116	[¹⁸ F]RO948 tau PET in bvFTD due to <i>C9orf72</i> and <i>GRN</i> mutations. Alzheimer's and Dementia, 2021, 17, .	0.4	0
117	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055011.	0.4	0
118	Head-to-head comparison of tau positron emission tomography tracers [18F]flortaucipir and [18F]RO948. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 342-354.	3.3	61
119	Apathy and anxiety are early markers of Alzheimer's disease. Neurobiology of Aging, 2020, 85, 74-82.	1.5	103
120	Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. Neurobiology of Disease, 2020, 134, 104645.	2.1	16
121	Distinct tau PET patterns in atrophy–defined subtypes of Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 335-344.	0.4	73
122	Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia. Annals of Neurology, 2020, 87, 52-62.	2.8	46
123	Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. BMC Neurology, 2020, 20, 10.	0.8	50
124	Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. Brain, 2020, 143, 650-660.	3.7	68
125	Cerebrospinal Fluid Levels of Neurogranin in Parkinsonian Disorders. Movement Disorders, 2020, 35, 513-518.	2.2	22
126	Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain, 2020, 143, 3234-3241.	3.7	150

#	Article	IF	Citations
127	Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies. Nature Structural and Molecular Biology, 2020, 27, 1125-1133.	3.6	123
128	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
129	Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load. Neurology, 2020, 95, e2834-e2844.	1.5	14
130	Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer's dementia. Alzheimer's Research and Therapy, 2020, 12, 158.	3.0	10
131	Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease. Science Advances, 2020, 6, .	4.7	86
132	LifeTime and improving European healthcare through cell-based interceptive medicine. Nature, 2020, 587, 377-386.	13.7	108
133	Allele drop-out and the stochastic threshold. , 2020, , 89-110.		0
134	Low-template DNA. , 2020, , 111-128.		0
135	A qualitative (semi-continuous) model: LRmix Studio. , 2020, , 153-179.		0
136	Investigative forensic genetics: SmartRank, CaseSolver and DNAmatch2. , 2020, , 339-383.		0
137	Forensic genetics: the basics. , 2020, , 1-53.		2
138	Empirical characterization of DNA profiles. , 2020, , 55-88.		1
139	Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2020, 324, 772.	3.8	640
140	Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease. Neurobiology of Aging, 2020, 95, 143-153.	1.5	34
141	Comparing progression biomarkers in clinical trials of early Alzheimer's disease. Annals of Clinical and Translational Neurology, 2020, 7, 1661-1673.	1.7	27
142	Image reconstruction methods affect software-aided assessment of pathologies of [18F]flutemetamol and [18F]FDG brain-PET examinations in patients with neurodegenerative diseases. NeuroImage: Clinical, 2020, 28, 102386.	1.4	15
143	Differential expression of cerebrospinal fluid neuroinflammatory mediators depending on osteoarthritis pain phenotype. Pain, 2020, 161, 2142-2154.	2.0	11
144	Plasma <scp>NT1</scp> Tau is a Specific and Early Marker of Alzheimer's Disease. Annals of Neurology, 2020, 88, 878-892.	2.8	24

#	Article	IF	Citations
145	Modeling patient-specific tau spreading patterns in Alzheimer's disease: Towards precision medicine. Alzheimer's and Dementia, 2020, 16, e040587.	0.4	2
146	The accumulation rate of tau aggregates is higher in females and younger individuals. Alzheimer's and Dementia, 2020, 16, e043876.	0.4	2
147	Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routine-use protocol for CSF collection. Alzheimer's and Dementia, 2020, 16, e047394.	0.4	0
148	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. Nature Communications, 2020, 11, 6252.	5.8	36
149	High circulating levels of midregional proenkephalin A predict vascular dementia: a population-based prospective study. Scientific Reports, 2020, 10, 8027.	1.6	5
150	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ε4 carriers. Scientific Reports, 2020, 10, 8233.	1.6	17
151	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. JAMA Neurology, 2020, 77, 955.	4.5	136
152	The implications of different approaches to define AT(N) in Alzheimer disease. Neurology, 2020, 94, e2233-e2244.	1.5	80
153	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. Nature Communications, 2020, 11, 2612.	5.8	283
154	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. Journal of Alzheimer's Disease, 2020, 76, 27-31.	1.2	8
155	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. NeuroImage: Clinical, 2020, 27, 102310.	1.4	10
156	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. Neurobiology of Disease, 2020, 139, 104831.	2.1	49
157	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. Alzheimer's Research and Therapy, 2020, 12, 30.	3.0	14
158	Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease. Brain, 2020, 143, 1233-1248.	3.7	164
159	Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding. Magnetic Resonance in Medicine, 2020, 84, 1605-1623.	1.9	67
160	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. JAMA Neurology, 2020, 77, 632.	4.5	80
161	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nature Medicine, 2020, 26, 379-386.	15.2	643
162	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. Alzheimer's Research and Therapy, 2020, 12, 19.	3.0	29

#	ARTICLE	IF	CITATIONS
163	[18F]Flortaucipir distinguishes Alzheimer's disease from progressive supranuclear palsy pathology in a mixed-pathology case. Acta Neuropathologica, 2020, 139, 411-413.	3.9	6
164	Beta-blocker therapy and risk of vascular dementia: A population-based prospective study. Vascular Pharmacology, 2020, 125-126, 106649.	1.0	19
165	Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. Nature Communications, 2020, 11, 347.	5.8	185
166	Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort. Movement Disorders, 2020, 35, 1258-1263.	2.2	17
167	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. Nature Communications, 2020, 11, 1683.	5.8	252
168	Relationship between cortical iron and tau aggregation in Alzheimer's disease. Brain, 2020, 143, 1341-1349.	3.7	101
169	Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Science Advances, 2020, 6, eaaz2387.	4.7	202
170	Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurology, The, 2020, 19, 422-433.	4.9	668
171	The A4 study: *β*-amyloid and cognition in 4432 cognitively unimpaired adults. Annals of Clinical and Translational Neurology, 2020, 7, 776-785.	1.7	43
172	Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults. Neurobiology of Aging, 2020, 93, 1-15.	1.5	11
173	Pre-analytical protocol for measuring Alzheimer's disease biomarkers in fresh CSF. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12137.	1.2	20
174	Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. Nature Communications, 2020, 11, 619.	5.8	67
175	The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Brain, 2020, 143, 3805-3815.	3.7	65
176	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. Neurology, 2020, 95, e3026-e3035.	1.5	31
177	Exploring causality of the association between smoking and Parkinson's disease. International Journal of Epidemiology, 2019, 48, 912-925.	0.9	70
178	Regional times to equilibria and their impact on semi-quantification of [18F]AV-1451 uptake. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2223-2232.	2.4	5
179	β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. Scientific Reports, 2019, 9, 11180.	1.6	28
180	European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 538-549.	1.2	17

#	Article	IF	Citations
181	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism and Related Disorders, 2019, 66, 158-165.	1.1	12
182	Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology, 2019, 93, e322-e333.	1.5	96
183	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease. Clinical Mass Spectrometry, 2019, 14, 74-82.	1.9	9
184	Staging **β**-Amyloid Pathology With Amyloid Positron Emission Tomography. JAMA Neurology, 2019, 76, 1319.	4.5	149
185	Towards a unified protocol for handling of CSF before β-amyloid measurements. Alzheimer's Research and Therapy, 2019, 11, 63.	3.0	38
186	Engineered antibodies: new possibilities for brain PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2848-2858.	3.3	49
187	Primary fatty amides are potential plasma biomarkers for AD. Nature Reviews Neurology, 2019, 15, 498-499.	4.9	0
188	α-synuclein–lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 15226-15235.	3.3	33
189	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. Radiology, 2019, 293, 646-653.	3.6	20
190	Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid. Communications Biology, 2019, 2, 365.	2.0	46
191	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. EMBO Molecular Medicine, 2019, 11, e11170.	3.3	228
192	Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. Acta Neuropathologica Communications, 2019, 7, 169.	2.4	146
193	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. Scientific Reports, 2019, 9, 15417.	1.6	11
194	Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 87.	3.0	30
195	Increased functional connectivity of thalamic subdivisions in patients with Parkinson's disease. PLoS ONE, 2019, 14, e0222002.	1.1	20
196	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
197	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. Alzheimer's Research and Therapy, 2019, 11, 82.	3.0	51
198	Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline. Neuroradiology, 2019, 61, 397-404.	1.1	5

#	Article	IF	Citations
199	Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 570-580.	0.4	84
200	Elecsys® Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. Clinical Biochemistry, 2019, 72, 30-38.	0.8	60
201	Method comparison study of the Elecsys® Î²-Amyloid (1â€"42) CSF assay versus comparator assays and LC-MS/MS. Clinical Biochemistry, 2019, 72, 7-14.	0.8	30
202	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. JAMA Neurology, 2019, 76, 1035.	4.5	455
203	Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimerâ€™s disease. PLoS ONE, 2019, 14, e0218561.	1.1	16
204	A new perspective for advanced positron emission tomographyâ€"based molecular imaging in neurodegenerative proteinopathies. Alzheimer's and Dementia, 2019, 15, 1081-1103.	0.4	16
205	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Diseaseâ€"Related Î²-Amyloid Status. JAMA Neurology, 2019, 76, 1060.	4.5	282
206	CSF placental growth factor â€" a novel candidate biomarker of frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 863-872.	1.7	9
207	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	0.9	19
208	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 69, 1213-1220.	1.2	12
209	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. Npj Parkinson's Disease, 2019, 5, 7.	2.5	40
210	Application of advanced brain positron emission tomographyâ€"based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	1.2	9
211	Advantages and disadvantages of the use of the CSF Amyloid Î² (AÎ²) 42/40 ratio in the diagnosis of Alzheimerâ€™s Disease. Alzheimer's Research and Therapy, 2019, 11, 34.	3.0	325
212	18F-Flortaucipir in TDP-43 associated frontotemporal dementia. Scientific Reports, 2019, 9, 6082.	1.6	26
213	Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. Scientific Reports, 2019, 9, 6079.	1.6	18
214	Extreme sleep pattern in Lewy body dementia: a hypothalamic matter?. BMJ Case Reports, 2019, 12, e228177.	0.2	3
215	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. Cerebral Cortex, 2019, 29, 2173-2182.	1.6	39
216	Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. Human Brain Mapping, 2019, 40, 2529-2545.	1.9	103

#	Article	IF	Citations
217	CSF and blood biomarkers for Parkinson's disease. Lancet Neurology, The, 2019, 18, 573-586.	4.9	393
218	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. Scientific Reports, 2019, 9, 2460.	1.6	7
219	P4â€531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO Î²â€AMYLOID POSITIVITY. Alzheimer's and Dementia, 2019, 15, P1517.	0.4	0
220	P4â€540: CSF PTAUâ€217 PERFORMS BETTER THAN PTAUâ€181 IN DETECTING ABNORMAL RETENTION OF ¹⁸Fâ€FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS. Alzheimer's and Dementia, 2019, 15, P1523.	0.4	1
221	P1588Beta-blocker therapy and risk of dementia: a population-based prospective study. European Heart Journal, 2019, 40, .	1.0	0
222	P4â€473: A NOVEL MASS SPECTROMETRIC METHOD FOR THE ABSOLUTE QUANTIFICATION OF SIX AÎ² PEPTIDES IN HUMAN CEREBROSPINAL FLUID. Alzheimer's and Dementia, 2019, 15, P1492.	0.4	0
223	DTâ€01â€04: DIAGNOSTIC PERFORMANCE OF [¹⁸F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDERâ€2 STUDY. Alzheimer's and Dementia, 2019, 15, P1485.	0.4	0
224	Cognitively normal women with Alzheimerâ€™s disease proteinopathy show relative preservation of memory but not of hippocampal volume. Alzheimer's Research and Therapy, 2019, 11, 109.	3.0	14
225	Predicting clinical decline and conversion to Alzheimerâ€™s disease or dementia using novel Elecsys AÎ²(1â€"42), pTau and tTau CSF immunoassays. Scientific Reports, 2019, 9, 19024.	1.6	123
226	Brain myoinositol as a potential marker of amyloid-related pathology. Neurology, 2019, 92, e395-e405.	1.5	30
227	Associations between tau, AÎ², and cortical thickness with cognition in Alzheimer disease. Neurology, 2019, 92, e601-e612.	1.5	196
228	Dataâ€driven approaches for tauâ€PET imaging biomarkers in Alzheimer's disease. Human Brain Mapping, 2019, 40, 638-651.	1.9	27
229	Accurate risk estimation of Î²â€amyloid positivity to identify prodromal Alzheimer's disease: Crossâ€validation study of practical algorithms. Alzheimer's and Dementia, 2019, 15, 194-204.	0.4	49
230	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimerâ€™s disease. Acta Neuropathologica, 2019, 137, 279-296.	3.9	128
231	Correlation of In Vivo [¹⁸F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. JAMA Neurology, 2019, 76, 310.	4.5	84
232	Parkinsonâ€™s disease: evolution of cognitive impairment and CSF AÎ²_{1â€"42} profiles in a prospective longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 165-170.	0.9	14
233	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. ELife, 2019, 8, .	2.8	57
234	CSF biomarkers of Alzheimer's disease concord with amyloidâ€Î² PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer's and Dementia, 2018, 14, 1470-1481.	0.4	468

#	Article	IF	Citations
235	Systematic Development of Small Molecules to Inhibit Specific Microscopic Steps of Amyloid-Beta42 Aggregation in Alzheimer's Disease. Biophysical Journal, 2018, 114, 225a.	0.2	2
236	Amyloid blood biomarker detects Alzheimer's disease. EMBO Molecular Medicine, 2018, 10, .	3.3	145
237	Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study. Neuroradiology, 2018, 60, 247-254.	1.1	23
238	Amyloid pathology in the progression to mild cognitive impairment. Neurobiology of Aging, 2018, 64, 76-84.	1.5	27
239	Comparing ^{18}F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. Neurology, 2018, 90, e388-e395.	1.5	83
240	Altered structural network organization in cognitively normal individuals with amyloid pathology. Neurobiology of Aging, 2018, 64, 15-24.	1.5	30
241	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. Alzheimer's Research and Therapy, 2018, 10, 2.	3.0	25
242	Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?. Brain, 2018, 141, 1241-1244.	3.7	8
243	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. Cerebral Cortex, 2018, 28, 340-349.	1.6	28
244	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
245	18F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. Scientific Reports, 2018, 8, 4717.	1.6	59
246	Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms. Psychiatry Research - Neuroimaging, 2018, 275, 5-13.	0.9	39
247	Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people. Alzheimer's and Dementia, 2018, 14, 54-61.	0.4	21
248	Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease. Cerebral Cortex, 2018, 28, 3638-3649.	1.6	29
249	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
250	Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later. Neurology, 2018, 90, e73-e81.	1.5	76
251	P3â€413: HETEROGENEOUS TAUâ€PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P1263.	0.4	0
252	P3â€267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS. Alzheimer's and Dementia, 2018, 14, P1178.	0.4	1

#	ARTICLE	IF	CITATIONS
253	ICâ€Pâ€224: HETEROGENEOUS TAUâ€PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P182.	0.4	0
254	O2â€09â€02: A UNIFIED PREâ€ANALYTICAL PROTOCOL FOR HANDLING OF CSF SAMPLES BEFORE ANALYSES OF AD BIOMARKER LEVELS. Alzheimer's and Dementia, 2018, 14, P641.	0.4	0
255	ICâ€Pâ€036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NONâ€DEMENTED ELDERLY SUBJECTS. Alzheimer's and Dementia, 2018, 14, P39.	0.4	0
256	Genetic characterization of amyloid-Î² and tau network spread. Nature Medicine, 2018, 24, 1790-1792.	15.2	1
257	Prevalence of amyloidâ€Î² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
258	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. Nutrition Research, 2018, 60, 13-25.	1.3	12
259	Cerebrospinal fluid concentrations of inflammatory markers in Parkinsonâ€™s disease and atypical parkinsonian disorders. Scientific Reports, 2018, 8, 13276.	1.6	104
260	Discriminative Accuracy of [^{18}F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA - Journal of the American Medical Association, 2018, 320, 1151.	3.8	298
261	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. Alzheimer's and Dementia, 2018, 14, 1313-1333.	0.4	87
262	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology, 2018, 91, e867-e877.	1.5	207
263	Effects of APOE Îµ4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. Neurobiology of Aging, 2018, 71, 81-90.	1.5	15
264	Molecular properties underlying regional vulnerability to Alzheimerâ€™s disease pathology. Brain, 2018, 141, 2755-2771.	3.7	89
265	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2018, 10, 9.	3.0	17
266	Greater tau load and reduced cortical thickness in APOE Îµ4-negative Alzheimerâ€™s disease: a cohort study. Alzheimer's Research and Therapy, 2018, 10, 77.	3.0	56
267	The clinical significance of 10-m walk test standardizations in Parkinsonâ€™s disease. Journal of Neurology, 2018, 265, 1829-1835.	1.8	34
268	Genome editing (CRISPR-Cas9) to identify and characterise functional variants determining metformin response. , 2018, 13, .		0
269	Endogenous beta-cell CART regulates insulin secretion and transcription of beta-cell genes. Molecular and Cellular Endocrinology, 2017, 447, 52-60.	1.6	12
270	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	0.9	20

#	Article	IF	Citations
271	Blood-based NfL. Neurology, 2017, 88, 930-937.	1.5	369
272	Characterisation of artefacts and drop-in events using STR-validator and single-cell analysis. Forensic Science International: Genetics, 2017, 30, 57-65.	1.6	24
273	Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population‐based prospective study. Journal of Internal Medicine, 2017, 282, 94-101.	2.7	26
274	<scp>I</scp>ncreased basal ganglia binding of ¹⁸<scp>F‐AV‐1451</scp> in patients with progressive supranuclear palsy. Movement Disorders, 2017, 32, 108-114.	2.2	111
275	Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2017, 58, 14-29.	1.5	93
276	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. Annals of Clinical and Translational Neurology, 2017, 4, 226-235.	1.7	72
277	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. Brain, 2017, 140, e33-e33.	3.7	2
278	Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 196-213.	1.5	100
279	Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Acta Neuropathologica, 2017, 133, 149-151.	3.9	61
280	Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E200-E208.	3.3	180
281	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiology of Aging, 2017, 51, 104-112.	1.5	154
282	Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process. International Journal of Legal Medicine, 2017, 131, 303-317.	1.2	25
283	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. Proteomics - Clinical Applications, 2017, 11, 1700100.	0.8	28
284	Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nature Communications, 2017, 8, 1214.	5.8	596
285	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. Scientific Reports, 2017, 7, 13333.	1.6	45
286	[IC‐02‐05]: ABNORMAL STRUCTURAL BRAIN CONNECTOME IN INDIVIDUALS WITH PRECLINICAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P7.	0.4	3
287	N-Terminal Prosomatostatin and Risk of Vascular Dementia. Cerebrovascular Diseases, 2017, 44, 259-265.	0.8	5
288	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiology of Aging, 2017, 59, 1-9.	1.5	84

#	Article	IF	Citations
289	No independent association between pulse wave velocity and dementia. Journal of Hypertension, 2017, 35, 2462-2467.	0.3	18
290	In vivo retention of ^{18}F-AV-1451 in corticobasal syndrome. Neurology, 2017, 89, 845-853.	1.5	103
291	^{18}F‑AV‑1451 and CSF T‑tau and P‑tau as biomarkers in Alzheimer's disease. EMBO Molecular Medicine, 2017, 9, 1212-1223.	3.3	156
292	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. BMJ Open, 2017, 7, e018177.	0.8	4
293	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. Lancet Neurology, The, 2017, 16, 661-676.	4.9	464
294	MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?. American Journal of Neuroradiology, 2017, 38, 1737-1741.	1.2	50
295	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1‑42)/Aβ(1‑40). Alzheimer's Research and Therapy, 2017, 9, 40.	3.0	17
296	Psychometric testing of a Swedish version of the Apathy Evaluation Scale. Nordic Journal of Psychiatry, 2017, 71, 477-484.	0.7	5
297	Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. Brain, 2017, 140, 98-117.	3.7	116
298	Modeling Strategies for Quantification of In Vivo ^{18}F-AV-1451 Binding in Patients with Tau Pathology. Journal of Nuclear Medicine, 2017, 58, 623-631.	2.8	53
299	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurology, 2017, 74, 1492.	4.5	97
300	[IC‑P‑123]: ATROPHY OF THE POSTERIOR SUBICULUM IS ASSOCIATED WITH MEMORY IMPAIRMENT, TAU AND Aβ PATHOLOGY IN NON‑DEMENTED INDIVIDUALS. Alzheimer's and Dementia, 2017, 13, P94.	0.4	0
301	[P3‑132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P985.	0.4	0
302	[P3‑402]: PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE AND AMYLOID PATHOLOGY EXHIBIT SIGNIFICANT BRAIN ATROPHY, TAU PATHOLOGY AND MILD MEMORY DIFFICULTIES. Alzheimer's and Dementia, 2017, 13, P1117.	0.4	0
303	[P4‑152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF β‑AMYLOID (1‑42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS. Alzheimer's and Dementia, 2017, 13, P1316.	0.4	1
304	[P4‑197]: EMERGING AMYLOID PATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1340.	0.4	0
305	[P1‑150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN *IL1RAP* AND ALZHEIMER's‑RELATED CSF‑BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P300.	0.4	0
306	[IC‑P‑098]: ASSOCIATION BETWEEN CEREBROSPINAL FLUID AND PLASMA NEURODEGENERATION BIOMARKERS WITH BRAIN ATROPHY IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P75.	0.4	0

#	Article	IF	Citations
307	[ICâ€Pâ€199]: [18]Fâ€AVâ€1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION. Alzheimer's and Dementia, 2017, 13, P146.	0.4	0
308	[P2â€"246]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER's DISEASE AND TAUOPATHIES. Alzheimer's and Dementia, 2017, 13, P706.	0.4	0
309	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimerâ€™s disease. Brain, 2017, 140, 2286-2294.	3.7	149
310	1947Biomarkers of microvascular endothelial dysfunction may predict dementia. European Heart Journal, 2017, 38, .	1.0	0
311	P4237N-terminal prosomatostatin predicts vascular dementia but not alzheimers disease. European Heart Journal, 2017, 38, .	1.0	0
312	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and AÎ² Pathology in Non-demented Individuals. Frontiers in Aging Neuroscience, 2017, 9, 306.	1.7	30
313	Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. Frontiers in Neuroscience, 2017, 11, 167.	1.4	87
314	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. Frontiers in Neuroscience, 2017, 11, 281.	1.4	62
315	The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer's disease. PLoS ONE, 2017, 12, e0185239.	1.1	32
316	Preclinical effects of APOE Îµ4 on cerebrospinal fluid AÎ²42 concentrations. Alzheimer's Research and Therapy, 2017, 9, 87.	3.0	22
317	A Genetic Variant of the Sortilin 1 Gene isÂAssociated with Reduced Risk ofÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 53, 1353-1363.	1.2	28
318	Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid AÎ²42 and the Ratios of AÎ² Isoforms Using Low Protein Binding Tubes. Journal of Alzheimer's Disease, 2016, 53, 1121-1132.	1.2	60
319	18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain, 2016, 139, 2372-2379.	3.7	149
320	Reply: Do we still need positron emission tomography for early Alzheimerâ€™s disease diagnosis?. Brain, 2016, 139, e61-e61.	3.7	5
321	Cerebral white matter lesions â€" associations with AÎ² isoforms and amyloid PET. Scientific Reports, 2016, 6, 20709.	1.6	52
322	Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Molecular Medicine, 2016, 8, 1184-1196.	3.3	219
323	Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimerâ€™s Disease Patient with Presenilin-1 Mutation. Journal of Alzheimer's Disease, 2016, 51, 339-343.	1.2	30
324	P4â€339: Earlyâ€and Lateâ€Onset Alzheimerâ€™S Disease are Associated with Distinct Regional TAU Pathology as Examined with [18]Fâ€AVâ€1451 TAU Positron Emission Tomography. Alzheimer's and Dementia, 2016, 12, P1164.	0.4	0

#	ARTICLE	IF	CITATIONS
325	Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. Journal of Parkinson's Disease, 2016, 6, 99-108.	1.5	6
326	The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 41.	3.0	121
327	Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium. Journal of Alzheimer's Disease, 2016, 55, 371-379.	1.2	35
328	Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Brain, 2016, 139, 1226-1236.	3.7	292
329	Myo-inositol changes precede amyloid pathology and relate to *APOE* genotype in Alzheimer disease. Neurology, 2016, 86, 1754-1761.	1.5	66
330	Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?. Lancet Neurology, The, 2016, 15, 650-651.	4.9	10
331	Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology, 2016, 86, 1747-1748.	1.5	4
332	Cognitive and functional changes associated with $A\beta$ pathology and the progression to mild cognitive impairment. Neurobiology of Aging, 2016, 48, 172-181.	1.5	28
333	External validation of a 3-step falls prediction model in mild Parkinson's disease. Journal of Neurology, 2016, 263, 2462-2469.	1.8	25
334	Plasma tau in Alzheimer disease. Neurology, 2016, 87, 1827-1835.	1.5	371
335	Cerebrospinal fluid neurogranin and YKL $\text{â€}40$ as biomarkers of Alzheimer's disease. Annals of Clinical and Translational Neurology, 2016, 3, 12-20.	1.7	137
336	Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. Movement Disorders, 2016, 31, 898-905.	2.2	136
337	Assessing risk for preclinical $\beta\text{â€}$amyloid pathology with *APOE*, cognitive, and demographic information. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 76-84.	1.2	49
338	Reference measurement procedure for CSF amyloid beta ($A\beta$)$_{1\text{â€}42}$ and the CSF $A\beta_{1\text{â€}42}$/$A\beta_{1\text{â€}40}$ ratio â€" a crossâ€validation study against amyloid PET. Journal of Neurochemistry, 2016, 139, 651-658.	2.1	78
339	The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson's disease and healthy controls. Quality of Life Research, 2016, 25, 2571-2577.	1.5	9
340	Plasma β-amyloid in Alzheimer's disease and vascular disease. Scientific Reports, 2016, 6, 26801.	1.6	442
341	Brain activity and Alzheimer's disease: a complex relationship. Brain, 2016, 139, 2109-2110.	3.7	3
342	Increased amyloidogenic APP processing in APOE É›4-negative individuals with cerebral β-amyloidosis. Nature Communications, 2016, 7, 10918.	5.8	48

#	Article	IF	Citations
343	Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. Alzheimer's Research and Therapy, 2016, 8, 17.	3.0	105
344	Cerebrospinal fluid Aβ42/Aβ40 and Aβ42/Aβ38 as biomarkers of Alzheimer's disease. Neurobiology of Aging, 2016, 39, S28.	1.5	5
345	Decreased ratio between β-amyloid 42 (Aβ42) and Aβ40 in cerebral spinal fluid is a better predictor of structural brain changes than Aβ42 alone in cognitively normal elderly people. Neurobiology of Aging, 2016, 39, S17.	1.5	0
346	<scp>CSF</scp> A<i>β</i>42/A<i>β</i>40 and A<i>β</i>42/A<i>β</i>38 ratios: better diagnostic markers of Alzheimer disease. Annals of Clinical and Translational Neurology, 2016, 3, 154-165.	1.7	329
347	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. PLoS ONE, 2016, 11, e0157755.	1.1	35
348	Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer's disease and other neurodegenerative diseases. EuPA Open Proteomics, 2015, 8, 137-143.	2.5	34
349	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9‑year study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 403-411.	1.2	26
350	Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis. Fluids and Barriers of the CNS, 2015, 12, 22.	2.4	6
351	Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. Alzheimer's Research and Therapy, 2015, 7, 63.	3.0	20
352	Prediction of Falls and/or Near Falls in People with Mild Parkinson's Disease. PLoS ONE, 2015, 10, e0117018.	1.1	57
353	Spatial navigation measured by the Floor Maze Test in patients with subjective cognitive impairment, mild cognitive impairment, and mild Alzheimer's disease. International Psychogeriatrics, 2015, 27, 1401-1409.	0.6	27
354	Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. Neurodegenerative Diseases, 2015, 15, 331-338.	0.8	16
355	Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness. Cerebrovascular Diseases Extra, 2015, 5, 41-51.	0.5	33
356	CSF biomarkers and clinical progression of Parkinson disease. Neurology, 2015, 84, 57-63.	1.5	178
357	An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics—Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer's Disease. Journal of Proteome Research, 2015, 14, 654-663.	1.8	84
358	Low <scp>IL</scp>‑8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. Acta Psychiatrica Scandinavica, 2015, 131, 269-278.	2.2	62
359	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 1180-1190.	0.4	254
360	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 2015, 138, 2701-2715.	3.7	109

#	Article	IF	Citations
361	Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease. BMC Neurology, 2015, 15, 8.	0.8	1
362	Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. Alzheimer's and Dementia, 2015, 11, 249.	0.4	101
363	Genotyping and interpretation of STR-DNA: Low-template, mixtures and database matches—Twenty years of research and development. Forensic Science International: Genetics, 2015, 18, 100-117.	1.6	116
364	Amyloid biomarkers in Alzheimer's disease. Trends in Pharmacological Sciences, 2015, 36, 297-309.	4.0	404
365	Less pronounced response to exercise in healthy relatives to type 2 diabetic subjects compared with controls. Journal of Applied Physiology, 2015, 119, 953-960.	1.2	13
366	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Neuroradiology, 2015, 57, 1079-1091.	1.1	37
367	Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology, 2015, 85, 1834-1842.	1.5	109
368	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. Alzheimer's Research and Therapy, 2015, 7, 40.	3.0	104
369	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. Neurology, 2015, 85, 1240-1249.	1.5	288
370	β-amyloid Peptides and Amyloid Plaques in Alzheimer's Disease. Neurotherapeutics, 2015, 12, 3-11.	2.1	195
371	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. PLoS ONE, 2015, 10, e0135458.	1.1	85
372	Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson's Disease Dementia. PLoS ONE, 2015, 10, e0141825.	1.1	75
373	Increased Levels of Hyaluronic Acid in Cerebrospinal Fluid in Patients with Vascular Dementia. Journal of Alzheimer's Disease, 2014, 42, 1435-1441.	1.2	33
374	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Molecular Neurodegeneration, 2014, 9, 53.	4.4	216
375	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42. JAMA Neurology, 2014, 71, 1282.	4.5	300
376	Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease. JAMA Psychiatry, 2014, 71, 1183.	6.0	85
377	A porous silicon immunoassay platform for fluorometric determination of α-synuclein in human cerebrospinal fluid. Mikrochimica Acta, 2014, 181, 1143-1149.	2.5	7
378	Factors associated with fear of falling in people with Parkinson's disease. BMC Neurology, 2014, 14, 19.	0.8	77

#	Article	IF	Citations
379	Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies. Journal of Alzheimer's Disease, 2014, 40, 343-350.	1.2	16
380	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathologica, 2014, 127, 633-643.	3.9	120
381	Extensive changes in the transcriptional profile of human adipose tissue including genes involved in oxidative phosphorylation after a 6‑month exercise intervention. Acta Physiologica, 2014, 211, 188-200.	1.8	62
382	Assessment of Peptide Chemical Modifications on the Development of an Accurate and Precise Multiplex Selected Reaction Monitoring Assay for Apolipoprotein E Isoforms. Journal of Proteome Research, 2014, 13, 1077-1087.	1.8	60
383	Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13924-13929.	3.3	407
384	Flt3 ligand does not differentiate between Parkinsonian disorders. Movement Disorders, 2014, 29, 1319-1322.	2.2	9
385	STR-validator: An open source platform for validation and process control. Forensic Science International: Genetics, 2014, 13, 154-166.	1.6	16
386	Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. BMC Neurology, 2014, 14, 64.	0.8	46
387	The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?. Alzheimer's and Dementia, 2014, 10, 713.	0.4	249
388	Expression of Phosphofructokinase in Skeletal Muscle Is Influenced by Genetic Variation and Associated With Insulin Sensitivity. Diabetes, 2014, 63, 1154-1165.	0.3	41
389	Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. Alzheimer's Research and Therapy, 2014, 6, 25.	3.0	169
390	CSF biomarkers for Alzheimer's pathology and the effect size of APOE É›4. Molecular Psychiatry, 2014, 19, 148-149.	4.1	30
391	P4-023: INCREASED LEVELS OF ANGIOGENIC FACTORS IN THE CEREBROSPINAL FLUID ARE ASSOCIATED WITH COGNITIVE IMPAIRMENT IN PARKINSOƒS DISEASE. , 2014, 10, P791-P791.		0
392	P2-101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE. , 2014, 10, P508-P508.		0
393	Fluid biomarkers in Alzheimer's disease – current concepts. Molecular Neurodegeneration, 2013, 8, 20.	4.4	180
394	Plasma tau levels in Alzheimer's disease. Alzheimer's Research and Therapy, 2013, 5, 9.	3.0	328
395	NG2 cells, a new trail for Alzheimer's disease mechanisms?. Acta Neuropathologica Communications, 2013, 1, 7.	2.4	50
396	Evaluation of the Cerebrospinal Fluid Amyloid-β_{1-42}/Amyloid-β_{1-40} Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders. Dementia and Geriatric Cognitive Disorders, 2013, 36, 99-110.	0.7	45

#	Article	IF	Citations
397	Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease. Brain Research, 2013, 1513, 117-126.	1.1	43
398	Free open source software for internal validation of forensic STR typing kits. Forensic Science International: Genetics Supplement Series, 2013, 4, e300-e301.	0.1	1
399	Aβ1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases. NeuroMolecular Medicine, 2013, 15, 169-179.	1.8	13
400	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1729-1737.	1.3	66
401	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. Psychoneuroendocrinology, 2013, 38, 1058-1066.	1.3	38
402	Cerebrospinal fluid inflammatory markers in Parkinson's disease – Associations with depression, fatigue, and cognitive impairment. Brain, Behavior, and Immunity, 2013, 33, 183-189.	2.0	214
403	Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology, 2013, 38, 853-862.	1.3	53
404	Link Between GIP and Osteopontin in Adipose Tissue and Insulin Resistance. Diabetes, 2013, 62, 2088-2094.	0.3	75
405	A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of Aβ38, Aβ40, and Aβ42 in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls. Journal of Alzheimer's Disease, 2013, 33, 1021-1032.	1.2	100
406	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2013, 28, 738-744.	1.3	22
407	Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 113-122.	0.6	20
408	Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis. Neurology, 2013, 80, 829-838.	1.5	138
409	Diagnostic Power of 24S-Hydroxycholesterol in Cerebrospinal Fluid: Candidate Marker of Brain Health. Journal of Alzheimer's Disease, 2013, 36, 739-747.	1.2	34
410	Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia. Journal of Alzheimer's Disease, 2013, 34, 673-679.	1.2	37
411	Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy. PLoS ONE, 2013, 8, e53250.	1.1	123
412	Proinflammatory Cytokines Are Elevated in Serum of Patients with Multiple System Atrophy. PLoS ONE, 2013, 8, e62354.	1.1	40
413	Assessment of Global and Regional Diffusion Changes along White Matter Tracts in Parkinsonian Disorders by MR Tractography. PLoS ONE, 2013, 8, e66022.	1.1	29
414	Cerebrospinal Fluid (CSF) 25-Hydroxyvitamin D Concentration and CSF Acetylcholinesterase Activity Are Reduced in Patients with Alzheimer's Disease. PLoS ONE, 2013, 8, e81989.	1.1	45

#	Article	IF	Citations
415	Evaluating Amyloid-Î² Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimerâ€™s Disease. PLoS ONE, 2013, 8, e66381.	1.1	119
416	Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia. Journal of Alzheimer's Disease, 2012, 33, 45-53.	1.2	106
417	Cerebrospinal Fluid Levels ofÎ²-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia. Archives of General Psychiatry, 2012, 69, 98.	13.8	554
418	Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology, 2012, 78, 468-476.	1.5	154
419	Evaluation of Plasma AÎ² as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study. Journal of Alzheimer's Disease, 2012, 28, 231-238.	1.2	48
420	Telomere length in blood and skeletal muscle in relation to measures of glycaemia and insulinaemia. Diabetic Medicine, 2012, 29, e377-81.	1.2	22
421	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1599-1608.	1.5	52
422	Impact of an Exercise Intervention on DNA Methylation in Skeletal Muscle From First-Degree Relatives of Patients With Type 2 Diabetes. Diabetes, 2012, 61, 3322-3332.	0.3	334
423	First-Degree Relatives of Type 2 Diabetic Patients Have Reduced Expression of Genes Involved in Fatty Acid Metabolism in Skeletal Muscle. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E1332-E1337.	1.8	21
424	CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly. Dementia and Geriatric Cognitive Disorders, 2012, 33, 156-163.	0.7	14
425	Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders. Archives of Neurology, 2012, 69, 1445.	4.9	407
426	Identification of SPARC-like 1 Protein as Part of a Biomarker Panel for Alzheimer's Disease in Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2012, 28, 625-636.	1.2	50
427	Amyloid-Î² Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 171-176.	1.2	95
428	Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimerâ€™s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study. PLoS ONE, 2012, 7, e38639.	1.1	73
429	Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease. PLoS ONE, 2012, 7, e29868.	1.1	106
430	Non-Motor Symptoms in Patients with Parkinsonâ€™s Disease â€" Correlations with Inflammatory Cytokines in Serum. PLoS ONE, 2012, 7, e47387.	1.1	180
431	Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimerâ€™s disease. Journal of Neural Transmission, 2012, 119, 789-797.	1.4	67
432	Monte Carlo feature selection and rule-based models to predict Alzheimerâ€™s disease in mild cognitive impairment. Journal of Neural Transmission, 2012, 119, 821-831.	1.4	13

#	Article	IF	Citations
433	Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study. Experimental Gerontology, 2012, 47, 179-182.	1.2	44
434	CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease. PLoS ONE, 2012, 7, e30525.	1.1	209
435	No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease. PLoS ONE, 2012, 7, e50237.	1.1	36
436	Differences in Survival between Patients with Dementia with Lewy Bodies and Patients with Alzheimer's Disease - Measured from a Fixed Cognitive Level. Dementia and Geriatric Cognitive Disorders, 2011, 32, 408-416.	0.7	25
437	Evaluation of GeneMapperÂ®ID-X Mixture Analysis tool. Forensic Science International: Genetics Supplement Series, 2011, 3, e11-e12.	0.1	4
438	Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment. Biological Psychiatry, 2011, 70, 145-151.	0.7	24
439	Cerebrospinal Fluid Levels of sAPP<i>Î±</i> and sAPP<i>Î²</i> in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. International Journal of Alzheimer's Disease, 2011, 2011, 1-6.	1.1	19
440	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2011, 3, 1.	1.7	73
441	Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls. Journal of Alzheimer's Disease, 2011, 22, 1223-1230.	1.2	68
442	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population. Journal of Alzheimer's Disease, 2011, 24, 537-546.	1.2	68
443	Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. Clinical Endocrinology, 2011, 75, 301-308.	1.2	10
444	Cerebrospinal Fluid Microglial Markers in Alzheimerâ€™s Disease: Elevated Chitotriosidase Activity but Lack of Diagnostic Utility. NeuroMolecular Medicine, 2011, 13, 151-159.	1.8	104
445	Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. International Journal of Geriatric Psychiatry, 2011, 26, 206-213.	1.3	20
446	Pleiotropic Effects of GIP on Islet Function Involve Osteopontin. Diabetes, 2011, 60, 2424-2433.	0.3	83
447	Prediction of Alzheimerâ€™s Disease Using Midregional Proadrenomedullin and Midregional Proatrial Natriuretic Peptide. Journal of Clinical Psychiatry, 2011, 72, 556-563.	1.1	25
448	Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years. Journal of Alzheimer's Disease, 2010, 21, 1119-1128.	1.2	110
449	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. Brain Research, 2010, 1362, 13-22.	1.1	180
450	Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. International Journal of Geriatric Psychiatry, 2010, 25, 403-410.	1.3	109

#	Article	IF	Citations
451	Distinct cerebrospinal fluid amyloid Î² peptide signatures in sporadic and PSEN1A431E-associated familial Alzheimer's disease. Molecular Neurodegeneration, 2010, 5, 2.	4.4	79
452	Cystatin C Levels are Positively Correlated with both AÎ²42 and Tau Levels in Cerebrospinal Fluid in Persons with Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Controls. Journal of Alzheimer's Disease, 2010, 21, 471-478.	1.2	25
453	Converging Pathways of Chromogranin and Amyloid Metabolism in the Brain. Journal of Alzheimer's Disease, 2010, 20, 1039-1049.	1.2	19
454	Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults. Archives of Neurology, 2010, 67, 217-23.	4.9	99
455	Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People. Archives of Neurology, 2010, 67, 949.	4.9	407
456	Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. Neurobiology of Aging, 2010, 31, 215-223.	1.5	97
457	Evaluation of plasma AÎ²40 and AÎ²42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 357-367.	1.5	242
458	Evaluation of plasma AÎ²40 and AÎ²42 as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 541.	1.5	2
459	Soluble TNF receptors are associated with AÎ² metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiology of Aging, 2010, 31, 1877-1884.	1.5	101
460	CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology, 2010, 74, 1531-1537.	1.5	182
461	Low Incidence of Post-Lumbar Puncture Headache in 1,089 Consecutive Memory Clinic Patients. European Neurology, 2010, 63, 326-330.	0.6	99
462	A Quick Test of cognitive speed is sensitive in detecting early treatment response in alzheimer disease. Alzheimer's Research and Therapy, 2010, 2, 29.	3.0	29
463	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 2, 20.	3.0	78
464	AÎ²40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer's Disease. PLoS ONE, 2010, 5, e15725.	1.1	96
465	Cerebrospinal Fluid Total Tau Is Associated with Shorter Survival in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2009, 28, 314-319.	0.7	32
466	Can CSF biomarkers or preâ€treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?. International Journal of Geriatric Psychiatry, 2009, 24, 638-647.	1.3	33
467	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. International Journal of Geriatric Psychiatry, 2009, 24, 1405-1412.	1.3	72
468	Evolution of AÎ²42 and AÎ²40 levels and AÎ²42/AÎ²40 ratio in plasma during progression of Alzheimer's disease: A multicenter assessment. Journal of Nutrition, Health and Aging, 2009, 13, 205-208.	1.5	52

#	ARTICLE	IF	CITATIONS
469	Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiology of Aging, 2009, 30, 165-173.	1.5	69
470	CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies. Neurobiology of Aging, 2009, 30, 1265-1271.	1.5	38
471	Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. Neuroscience Letters, 2009, 450, 56-59.	1.0	37
472	Interleukin-6 Is Elevated in the Cerebrospinal Fluid of Suicide Attempters and Related to Symptom Severity. Biological Psychiatry, 2009, 66, 287-292.	0.7	436
473	Trace DNA collection—Performance of minitape and three different swabs. Forensic Science International: Genetics Supplement Series, 2009, 2, 189-190.	0.1	51
474	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
475	Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease. PLoS ONE, 2009, 4, e6294.	1.1	79
476	The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2008, 23, 192-198.	1.3	45
477	A fast analysis system for forensic DNA reference samples. Forensic Science International: Genetics, 2008, 2, 184-189.	1.6	22
478	A comparison of three automated DNA purification methods in Forensic casework. Forensic Science International: Genetics Supplement Series, 2008, 1, 76-77.	0.1	13
479	Automatic data processing of reference DNA-profiles from FTA and non-FTA samples. Forensic Science International: Genetics Supplement Series, 2008, 1, 29-31.	0.1	1
480	Proteinase K challenged by a novel protease. Forensic Science International: Genetics Supplement Series, 2008, 1, 32-34.	0.1	1
481	Elevated Cerebrospinal Fluid BACE1 Activity in Incipient Alzheimer Disease. Archives of Neurology, 2008, 65, 1102-7.	4.9	193
482	Prediction of Alzheimer's Disease Using a Cerebrospinal Fluid Pattern of C-Terminally Truncated β-Amyloid Peptides. Neurodegenerative Diseases, 2008, 5, 268-276.	0.8	32
483	Predicting Long-Term Cognitive Outcome with New Regression Models in Donepezil-Treated Alzheimer Patients in a Naturalistic Setting. Dementia and Geriatric Cognitive Disorders, 2008, 26, 203-211.	0.7	19
484	Cube Copying Test in Combination with rCBF or CSF Aβ_{42} Predicts Development of Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2008, 25, 544-552.	0.7	20
485	Electroencephalogram Variability in Dementia with Lewy Bodies, Alzheimer's Disease and Controls. Dementia and Geriatric Cognitive Disorders, 2008, 26, 284-290.	0.7	58
486	The Usefulness of Cube Copying for Evaluating Treatment of Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2008, 23, 439-446.	0.9	11

#	Article	IF	Citations
487	Prediction of Alzheimer's Disease Using the CSF Aβ42/Aβ40 Ratio in Patients with Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2007, 23, 316-320.	0.7	248
488	Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients With Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 366.	4.9	131
489	Cerebrospinal Fluid Biomarkers Predict Decline in Subjective Cognitive Function over 3 Years in Healthy Elderly. Dementia and Geriatric Cognitive Disorders, 2007, 24, 118-124.	0.7	148
490	Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. International Journal of Molecular Medicine, 2007, 20, 233.	1.8	6
491	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurology, The, 2006, 5, 228-234.	4.9	1,494
492	Lack of neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia. Experimental Brain Research, 2004, 154, 442-449.	0.7	35
493	Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. Brain Research, 2003, 970, 47-57.	1.1	117
494	Cyclosporin A and Bcl-2 do not inhibit quinolinic acid-induced striatal excitotoxicity in rodents. Experimental Neurology, 2003, 183, 430-437.	2.0	10
495	Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease. Neuron, 2002, 33, 849-860.	3.8	553
496	Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. Journal of Neurochemistry, 2001, 78, 694-703.	2.1	53
497	Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. European Journal of Neuroscience, 2001, 13, 206-210.	1.2	84
498	Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. European Journal of Neuroscience, 2001, 14, 1425-1435.	1.2	39
499	Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. European Journal of Neuroscience, 2001, 14, 1492-1504.	1.2	140
500	Improving the Survival of Grafted Dopaminergic Neurons: A Review over Current Approaches. Cell Transplantation, 2000, 9, 179-195.	1.2	327
501	Grafting of Nigral Tissue Hibernated with Tirilazad Mesylate and Glial Cell Line-Derived Neurotrophic Factor. Cell Transplantation, 2000, 9, 577-584.	1.2	20
502	Expression of TGF-β isoforms, TGF-β receptors, and SMAD molecules at different stages of human glioma. International Journal of Cancer, 2000, 89, 251-258.	2.3	206
503	Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. Brain Research, 2000, 857, 20-29.	1.1	89
504	Chapter 10 Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. Progress in Brain Research, 2000, 127, 203-231.	0.9	36

#	Article	IF	Citations
505	FK506 and Cyclosporin A Enhance the Survival of Cultured and Grafted Rat Embryonic Dopamine Neurons. Experimental Neurology, 2000, 164, 94-101.	2.0	40
506	Additive Effects of Caspase Inhibitor and Lazaroid on the Survival of Transplanted Rat and Human Embryonic Dopamine Neurons. Experimental Neurology, 2000, 164, 102-111.	2.0	80
507	Caspase inhibition reduces apoptosis and increases survival of nigral transplants. Nature Medicine, 1999, 5, 97-100.	15.2	279
508	Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 8727-8732.	3.3	215
509	Flunarizine improves the survival of grafted dopaminergic neurons. Neuroscience, 1999, 94, 17-20.	1.1	33
510	Patterns of Cell Death and Dopaminergic Neuron Survival in Intrastriatal Nigral Grafts. Experimental Neurology, 1999, 160, 279-288.	2.0	85
511	Neuronal death in nigral grafts in the absence of poly (ADP-ribose) polymerase activation. NeuroReport, 1999, 10, 3347-3351.	0.6	12
512	Graft Survival. Journal of Neurosurgery, 1999, 90, 804-6.	0.9	4
513	Mitochondrial Control of Acute Glutamate Excitotoxicity in Cultured Cerebellar Granule Cells. Journal of Neuroscience, 1998, 18, 10277-10286.	1.7	197
514	A Case of XXXXY Sex Chromosome Anomaly with Autoradiographic Studies. Cytogenetic and Genome Research, 1963, 2, 208-231.	0.6	52